Stock Report

Download full stock data and analysis for free Last Updated: 12-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Zynerba Pharmaceuticals (ZYNE) Key Ratios

Stock Card factsheet share-fund-plan-icon

$1.30

$0.00 (0.00%)

As on 13-Oct-2023 09:30EDT

Market cap

info icon

$70 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -5.64 -20.64 -5.13 4.86 1.02
Net Profit -10.45 -2.27 2.64 5.78 1.77
EPS -6.66 15.56 16.03 16.34 11.73
Book Value -- -- -41.89 -32.01 -25.75
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info ---46,538.06------
Net Margin info -10,463.387,116.0849,625.92----
Return on equity info -63.70-61.12-98.36-59.45-57.38
Return on Capital info -63.37-60.90---59.00-57.09
Return on Assets info -53.90-52.15-57.62-50.95-48.45
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
-59.00
-57.09
-74.01
-47.07
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-98.36

Lower than Peers by 58.03

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
-98.36
-59.45
-57.38
-74.27
-47.20
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-57.62

Lower than Peers by 26.37

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
-57.62
-50.95
-48.45
-62.30
-40.54
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

49,625.92

Higher than Peers by 49,717.21

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
49,625.92
--
--
-10,463.38
21,542.91
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
-1.00
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-5.13

Lower than Peers by 4.11

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
-5.13
4.13
29.37
-51.70
14.25
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

2.64

Higher than Peers by 10.17

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
2.64
7.39
25.40
-60.35
21.24
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

16.03

Higher than Peers by 1.80

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
16.03
0.17
0.46
-0.27
0.40
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-58.14

Lower than Peers by 48.01

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
-58.14
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
0.01
0.01
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
0.01
0.00
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.43

Lower than Peers by 2.38

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
3.43
5.97
8.10
5.27
7.22
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.31

Lower than Peers by 2.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
3.31
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-25.05

Lower than Peers by 22.96

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
-25.05
-163.40
-68.27
--
--
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
-0.69
-3.08
-1.92
-4.46
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.54

Lower than Peers by 4.79

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
0.54
0.52
1.63
1.61
1.85
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.78

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
0.78
0.76
-1.34
-0.72
-2.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

70

Lower than Peers by 72

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Zynerba Pharmaceuticals (ZYNE)
70
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...